skip to main content

Chronic Hepatitis C — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGastroenterology & HepatologyChronic Hepatitis CRACP Adult Medicine

A 65-year-old man with chronic hepatitis C (genotype 1a) and compensated cirrhosis (Child-Pugh A) has never received antiviral treatment. According to current Australian PBS criteria, what is the recommended treatment regimen?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Sofosbuvir/velpatasvir for 12 weeks

Sofosbuvir/velpatasvir (Epclusa) for 12 weeks is a pan-genotypic DAA regimen listed on the PBS for chronic HCV. For compensated cirrhosis, 12 weeks is standard. Glecaprevir/pibrentasvir is an alternative pan-genotypic option (12 weeks for compensated cirrhosis). The shorter 8-week regimens are for non-cirrhotic patients. SVR rates exceed 95%. All Australians with chronic HCV are eligible for PBS-subsidised DAA therapy regardless of fibrosis stage.

Reference: Gastroenterological Society of Australia – 2022 – HCV Consensus; PBS – 2025 – DAA Listings